Certara®, a global leader in biosimulation, today announced that it has appointed Nicolette D. Sherman to the position of Chief Human Resources Officer (CHRO). Sherman joins Certara with extensive experience in the biopharmaceutical industry, leading HR strategy and implementing programs to drive business impact.
“We are pleased to have Nicolette join Certara as we continue to grow our high-performing team and capabilities worldwide,” said William F. Feehery, chief executive officer. “She has a proven track record of achieving organizational results through advancing corporate values and building competencies. We look forward to her contributions to Certara.”
Most recently, Sherman was CHRO at Oyster Point Pharma, where she developed the human resources function of the newly public biotech company, establishing the infrastructure needed to support commercialization. Prior to that, she served in multiple roles at Sanofi for 12 years, including Vice President of North American Human Resources Operations and Vice President of Global Leadership Development. Sherman was responsible for leading a large team of HR professionals, providing support across all areas of the employment cycle for the 5 diverse business units and all functional areas in North America.
“I am honored to join Certara and look forward to contributing to its important work in transforming drug development and bringing new therapies to market,” said Ms. Sherman. “Certara has impressive breadth and depth of scientific and regulatory expertise, and I am excited to play a role in continuing to build upon the world-class team.”
About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$10.71 |
Daily Change: | 0.16 1.52 |
Daily Volume: | 2,102,663 |
Market Cap: | US$1.720B |
December 02, 2024 November 06, 2024 September 18, 2024 August 15, 2024 August 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB